Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy
What Would A $5.8 Billion NIH Cut Look Like? Devastation

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!